Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers.
Affiliation
1 National Maternity Hospital, Holles Street, Dublin 2, Ireland. 2 UCD School of Medicine, National Maternity Hospital, Holles Street, Dublin 2, IrelandIssue Date
2018-01-01Keywords
PREGNANCYLocal subject classification
BIOMARKERS
Metadata
Show full item recordCitation
Helena C. Bartels, James D. Postle, Paul Downey, and Donal J. Brennan, “Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers,” Disease Markers, vol. 2018, Article ID 1507674, 11 pages, 2018. https://doi.org/10.1155/2018/1507674.Publisher
HindawiJournal
Disease MarkersDOI
10.1155/2018/1507674PubMed ID
3005764930057649
Abstract
Placenta accreta spectrum (PAS) is a condition of abnormal placental invasion encompassing placenta accreta, increta, and percreta and is a major cause of severe maternal morbidity and mortality. The diagnosis of a PAS is made on the basis of histopathologic examination and characterised by an absence of decidua and chorionic villi are seen to directly adjacent to myometrial fibres. The underlying molecular biology of PAS is a complex process that requires further research; for ease, we have divided these processes into angiogenesis, proliferation, and inflammation/invasion. A number of diagnostic serum biomarkers have been investigated in PAS, including human chorionic gonadotropin (HCG), pregnancy-associated plasma protein-A (PAPP-A), and alpha-fetoprotein (AFP). They have shown variable reliability and variability of measurement depending on gestational age at sampling. At present, a sensitive serum biomarker for invasive placentation remains elusive. In summary, there are a limited number of studies that have contributed to our understanding of the molecular biology of PAS, and additional biomarkers are needed to aid diagnosis and disease stratification.Item Type
ArticleLanguage
enISSN
1875-8630ae974a485f413a2113503eed53cd6c53
10.1155/2018/1507674
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
Related articles
- The Underlying Molecular Mechanisms of the Placenta Accreta Spectrum: A Narrative Review.
- Authors: Lizárraga-Verdugo E, Beltrán-Ontiveros SA, Gutiérrez-Grijalva EP, Montoya-Moreno M, Gutiérrez-Arzapalo PY, Avendaño-Félix M, Gutiérrez-Castro KP, Cuén-Lazcano DE, González-Quintero P, Mora-Palazuelos CE
- Issue date: 2024 Sep 8
- Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging.
- Authors: Jauniaux E, Collins S, Burton GJ
- Issue date: 2018 Jan
- Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
- Authors: Büke B, Akkaya H, Demir S, Sağol S, Şimşek D, Başol G, Barutçuoğlu B
- Issue date: 2018 Jan
- Biomarkers of abnormally invasive placenta.
- Authors: Al-Khan A, Youssef YH, Feldman KM, Illsley NP, Remache Y, Alvarez-Perez J, Mannion C, Alvarez M, Zamudio S
- Issue date: 2020 Feb
- Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete.
- Authors: Zhou J, Li J, Yan P, Ye YH, Peng W, Wang S, Wang XT
- Issue date: 2014 Sep